Impact of baseline mutations on response to ponatinib and end of treatment mutation analysis in patients with chronic myeloid leukemia.
Year: 2013
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Michael W. N. Deininger, Jorge E. Cortes, Dong-Wook Kim, Franck E. Nicolini, Moshe Talpaz, Michele Baccarani, Martin C. Müller, Stephanie Lustgarten, Victor M. Rivera, Tim Clackson, Christopher D. Turner, Frank G. Haluska, Francois Guilhot, Andreas Hochhaus, John M. Goldman, Neil P. Shah, Hagop M. Kantarjian, Timothy P. Hughes
Institutions: University of Utah, Huntsman Cancer Institute, The University of Texas MD Anderson Cancer Center, The Catholic University of Korea Seoul St. Mary's Hospital, Catholic University of Korea, Hôpital Lyon Sud, U-M Rogel Cancer Center, Heidelberg University, Medizinische Fakultät Mannheim, ARIAD Pharmaceuticals (United States), Inserm, Centre Hospitalier Universitaire de Poitiers, Jena University Hospital, Imperial College London, University of California, San Francisco, South Australia Pathology, Centre for Cancer Biology, The University of Adelaide
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2598889474